Omalizumab for the treatment of asthma: subspeciality in the district

J. Miles, K. Ballance, H. Ford (Manchester, United Kingdom)

Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Session: Aspects of uncontrolled asthma
Session type: Thematic Poster Session
Number: 1993
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Miles, K. Ballance, H. Ford (Manchester, United Kingdom). Omalizumab for the treatment of asthma: subspeciality in the district. Eur Respir J 2009; 34: Suppl. 53, 1993

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Finding asthmatics suitable for omalizumab therapy in a district hospital
Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment?
Year: 2013


Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting
Source: International Congress 2017 – Asthma management
Year: 2017


Does having specialist asthma nurses improve adherence to national asthma guidelines? A comparison between two UK district general hospitals
Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects
Year: 2015


Reduced healthcare resource utilization in asthma patients treated with omalizumab in the clinical practice in Spain
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015


Reason for non-compliance to inhaled medications among adult patients of asthma and COPD attending outpatient department in a tertiary care hospital
Source: International Congress 2016 – Asthma management in primary care
Year: 2016


What is new in paediatric asthma?
Source: Annual Congress 2006 - Paediatric year in review
Year: 2006


A virtual asthma clinic for children: Improved asthma control, less hospital visits
Source: International Congress 2015 – Paediatric asthma and allergy: e-health in management
Year: 2015

Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece.
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020


Omalizumab in severe allergic asthma: a 4-year real world experience, Fife, Scotland
Source: International Congress 2017 – Asthma management
Year: 2017


Emergency visits for asthma: asthma exacerbations or poor asthma control?
Source: Eur Respir J 2004; 24: Suppl. 48, 598s
Year: 2004

How are we managing our asthmatic patients? Asthma diagnosis and treatment in an urban primary care practice
Source: Eur Respir J 2004; 24: Suppl. 48, 85s
Year: 2004

Cost of asthma in patients treated with national asthma guideline in Turkey
Source: Eur Respir J 2003; 22: Suppl. 45, 481s
Year: 2003

Omalizumab: therapeutic approach to asthma and comorbidities
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Effectiveness of pharmacist intervention for asthma control improvement
Source: Eur Respir J 2008; 31: 790-799
Year: 2008



Asthma in pre-schoolers: difficult to treat
Source: Annual Congress 2005 - Asthma in the preschool child
Year: 2005

If the global initiative for asthma (GINA) reflected on the asthma therapy in Croatia?
Source: Eur Respir J 2001; 18: Suppl. 33, 46s
Year: 2001

Treatment of asthma exacerbations managed in primary care in Spain
Source: Eur Respir J 2001; 18: Suppl. 33, 235s
Year: 2001

Montelukast in paediatric asthma: where we are now and what still needs to be done?
Source: International Congress 2014 – Clinical Trial presentation and discussion "Cysteinyl leukotrienes and paediatric asthma: a new horizon or a blind alley?"
Year: 2014



The burden of paediatric asthma: economic and familiar
Source: Eur Respir Mon 2012; 56: 71-81
Year: 2012


Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective?
Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care
Year: 2008